BrainStorm CEO Steps Down, CMO Promoted; Phase 3b Trial for NurOwn Planned

BRAINSTORM CELL THERAPEUTICS INC.

Co-CEO Stacy Lindborg resigns effective May 9, 2024, but will join the Board of Directors.
Dr. Bob Dagher promoted from Chief Development Officer to Executive VP and Chief Medical Officer.
Company plans registrational Phase 3b trial for NurOwn (ALS) under FDA Special Protocol Assessment.
Separation agreement includes $300,000 lump sum payment and continued vesting of certain equity awards.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Stacy Lindborg

member of the Board

BCLI · BRAINSTORM CELL THERAPEUTICS INC.

Effective: 2024-05-09
Filed: April 17, 2024, 7:59 PM ET

Dr. Lindborg has been appointed to serve as a member of the Board, with effect from the Separation Date.

Departed

Stacy Lindborg

Co-Chief Executive Officer

BCLI · BRAINSTORM CELL THERAPEUTICS INC.

Effective: 2024-05-09
Filed: April 17, 2024, 7:59 PM ET

Dr. Stacy Lindborg, the Co-Chief Executive Officer of Brainstorm Cell Therapeutics Inc. (the “Company”), provided the Company with notice of her intent to resign from her current role at the Company, effective as of May 9, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stacy Lindborg was appointed as member of the Board at BRAINSTORM CELL THERAPEUTICS INC..

Action: appointed
Role: member of the Board

Exact text from the filing

Dr. Lindborg has been appointed to serve as a member of the Board, with effect from the Separation Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stacy Lindborg resigned as Co-Chief Executive Officer at BRAINSTORM CELL THERAPEUTICS INC..

Action: resigned
Role: Co-Chief Executive Officer

Exact text from the filing

Dr. Stacy Lindborg, the Co-Chief Executive Officer of Brainstorm Cell Therapeutics Inc. (the “Company”), provided the Company with notice of her intent to resign from her current role at the Company, effective as of May 9, 2024.

View on SEC.gov

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-047974

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.